Literature DB >> 27182510

TREATMENT OF BREAST CANCER: IMO STATE NIGERIA VERSUS INDIANA, USA WOMEN - COMPARATIVE ANALYTIC STUDY.

A A Anele1, M Bowling2, G J Eckert3, Elf Gonzalez4, H Kipfer5, C Sauder2.   

Abstract

BACKGROUND: Women with breast cancer undergo multimodal treatment for best outcome. This study seeks to identify the treatment challenges for such women in Imo State, Nigeria vis-à-vis similar women in Indiana USA. We compared the treatment modalities of both groups; noting predictors of compliance for subsequent action.
SETTING: Federal Medical Centre, Owerri; Imo State, Imo State University, Orlu, Nigeria and Indiana University Hospital, Indiana, USA.
DESIGN: A retrospective study.
METHODOLOGY: From 2000-2013, 100 randomly pulled charts of patients treated for pathologically confirmed breast cancer in Imo, Nigeria Federal Medical Centre Owerri, Imo State University Hospital; and Indiana University Hospital U.S. respectively were reviewed. The demographics, clinical and pathological data of the patients with confirmed breast cancer were obtained. The data were formatted and analyzed with SPSS version 16.0. The clinical features, management options, outcomes and specific features were compared for both groups using Wilcoxon Rank Sum tests (age, parity) and chi-square tests for all other variables. A 5% significance level was used for all tests.
RESULTS: One hundred patients were included for each group. The mean/minimum ages; Imo, Nigeria 41.7/21 (SD/SE 15.3/1.5) vs. Indiana, U.S.56.4/29 (SD 12.4/SE 1.2) p<0.0001. Histology for Indiana USA women was predominantly ductal carcinoma in situ (DCIS) P<0.0001 while that of Imo, Nigeria was invasive ductal carcinoma inflammatory cancer P<0.0326. Women in both locations received chemotherapy and surgery. Imo women received less radiotherapy. Toxicity from chemotherapy remained constant features for both groups, P<0.0001. In Indiana USA, the 5year survival exceeded 85%; In Imo Nigeria it was 10%. This study showed that Women on both locations who were likely to be compliant were those receiving mastectomy; Imo, Nigeria 44(56%) <0.013 vs. Indiana, U.S. 74(80%) p<0.0186; women with cosmesis given; Imo, Nigeria 41(42%) vs. Indiana, U.S. 91 (94%) p<0.0001. Sample sizes were inadequate to perform multivariable models.
CONCLUSION: The multimodal treatment regimen implied that there was need for an algorithm protocol for breast cancer women. Thus the need to improve the quality of treatment particularly in Nigeria by improved treatment documentation to overcome key barriers involving information exchange.

Entities:  

Keywords:  Breast cancer women; Compliance; Multimodality treatment

Year:  2014        PMID: 27182510      PMCID: PMC4866729     

Source DB:  PubMed          Journal:  J West Afr Coll Surg        ISSN: 2276-6944


  25 in total

Review 1.  Epidemiological risk factors for breast cancer--a review.

Authors:  M N Okobia; C H Bunker
Journal:  Niger J Clin Pract       Date:  2005-06       Impact factor: 0.968

Review 2.  Stereotactic core-needle biopsy of the breast: a report of the Joint Task Force of the American College of Radiology, American College of Surgeons, and College of American Pathologists.

Authors:  L Bassett; D P Winchester; R B Caplan; D D Dershaw; K Dowlatshahi; W P Evans; L L Fajardo; P L Fitzgibbons; D E Henson; R V Hutter; M Morrow; J R Paquelet; S E Singletary; J Curry; P Wilcox-Buchalla; M Zinninger
Journal:  CA Cancer J Clin       Date:  1997 May-Jun       Impact factor: 508.702

3.  Psychosexual functioning and body image following a diagnosis of ductal carcinoma in situ.

Authors:  Sharon L Bober; Anita Giobbie-Hurder; Karen M Emmons; Eric Winer; Ann Partridge
Journal:  J Sex Med       Date:  2012-07-19       Impact factor: 3.802

4.  The severity, outcome and challenges of breast cancer in Nigeria.

Authors:  A R K Adesunkanmi; O O Lawal; K A Adelusola; M A Durosimi
Journal:  Breast       Date:  2005-08-08       Impact factor: 4.380

5.  Contralateral primary tumors in breast cancer patients in a randomized trial of adjuvant tamoxifen therapy.

Authors:  L E Rutqvist; B Cedermark; U Glas; A Mattsson; L Skoog; A Somell; T Theve; N Wilking; J Askergren; M L Hjalmar
Journal:  J Natl Cancer Inst       Date:  1991-09-18       Impact factor: 13.506

6.  Fertility preservation and pregnancy in women with and without BRCA mutation-positive breast cancer.

Authors:  Kenny A Rodriguez-Wallberg; Kutluk Oktay
Journal:  Oncologist       Date:  2012-09-24

Review 7.  Breast cancer as a global health concern.

Authors:  Steven S Coughlin; Donatus U Ekwueme
Journal:  Cancer Epidemiol       Date:  2009-11-07       Impact factor: 2.984

Review 8.  Pathologic aspects of inflammatory breast cancer: part 2. Biologic insights into its aggressive phenotype.

Authors:  Yun Gong
Journal:  Semin Oncol       Date:  2008-02       Impact factor: 4.929

Review 9.  Beyond mammography: new frontiers in breast cancer screening.

Authors:  Jennifer S Drukteinis; Blaise P Mooney; Chris I Flowers; Robert A Gatenby
Journal:  Am J Med       Date:  2013-04-03       Impact factor: 4.965

10.  Inflammatory breast cancer.

Authors:  M P Moore; J K Ihde; J P Crowe; T P Hakes; D W Kinne
Journal:  Arch Surg       Date:  1991-03
View more
  1 in total

1.  Drivers of advanced stage at breast cancer diagnosis in the multicountry African breast cancer - disparities in outcomes (ABC-DO) study.

Authors:  Fiona McKenzie; Annelle Zietsman; Moses Galukande; Angelica Anele; Charles Adisa; Groesbeck Parham; Leeya Pinder; Herbert Cubasch; Maureen Joffe; Frederick Kidaaga; Robert Lukande; Awa U Offiah; Ralph O Egejuru; Aaron Shibemba; Joachim Schuz; Benjamin O Anderson; Isabel Dos Santos Silva; Valerie McCormack
Journal:  Int J Cancer       Date:  2017-12-23       Impact factor: 7.396

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.